BriaCell Therapeutics (BriaCell Therapeutics) Accounts Receivable : $0.03 Mil (As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. BriaCell Therapeutics's accounts receivables for the quarter that ended in Jan. 2024 was $0.03 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. BriaCell Therapeutics's Net-Net Working Capital per share for the quarter that ended in Jan. 2024 was $-0.88.

BriaCell Therapeutics Accounts Receivable Historical Data

The historical data trend for BriaCell Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Accounts Receivable Chart

BriaCell Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Accounts Receivable

Get a 7-Day Free Trial

0.02

0.01

0.02

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Accounts Receivable	Get a 7-Day Free Trial															0.01	0.02	0.02	0.02	0.03

BriaCell Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

BriaCell Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

BriaCell Therapeutics's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.03	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), BriaCell Therapeutics's accounts receivable are only considered to be worth 75% of book value:

BriaCell Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Jan. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(6.245	+	0.75 * 0.03	+	0.5 * 0	-	20.549
-	0	-	-0.244)	/	15.9817
=	-0.88

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

BriaCell Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

BCT:Canada

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Executives

Jamieson Bondarenko	director	402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub	director	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin	officer: CFO & Secretary	MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del	officer: Chief Medical Officer	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams	director, officer: President & CEO	620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg	director	201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago	officer: Chief Scientific Officer	2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony	director	P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig	director	4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3